Micronoma
  • Home
  • For Physicians
  • Oncobiota™ Platform
    • Our Approach
    • OncobiotaLUNGdetect
    • Other Applications
  • About Us
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Research Partners
    • Investors
    • Careers at Micronoma
    • For the Media
  • News & Resources
    • Micronoma in the News
    • Announcements
    • Micronoma Blog
    • FAQ’s
    • Micronoma and Microbiome
      Publications
  • Contact Us
Select Page
Micronoma Teams Up with NYU Grossman School of Medicine on Lung Cancer Research Grant Utilizing Microbial Biomarkers

Micronoma Teams Up with NYU Grossman School of Medicine on Lung Cancer Research Grant Utilizing Microbial Biomarkers

May 18, 2023

This latest collaboration seeks synergistic methodologies that will enable the earliest, best predictions of lung cancer May 18, 2023. SAN DIEGO, Calif.– Micronoma announced today that it is serving as the industry partner on a grant the NYU Grossman School of...
Micronoma Breaks Through With Microbiome-BIOTECH: FDA Designation a ‘Milestone’

Micronoma Breaks Through With Microbiome-BIOTECH: FDA Designation a ‘Milestone’

Feb 8, 2023

Micronoma’s microbiome platform is breaking into its next phase with validation from the U.S. Food and Drug Administration. Last month, the San Diego-based company announced that the FDA has given its OncobiotaLUNG assay Breakthrough Device Designation. The...
FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

Jan 30, 2023

The FDA has granted breakthrough device designation to the novel, microbiome-driven, liquid biopsy assay OncobiotaLUNG for the detection of lung carcinomas, according to a press release from developer Micronoma.1 The assay is one of the first blood microbiome­–driven...
In Brief This Week: Micronoma, Legend Biotech, Point Biopharma, AstraZeneca, Daiichi Sankyo, Takeda,

In Brief This Week: Micronoma, Legend Biotech, Point Biopharma, AstraZeneca, Daiichi Sankyo, Takeda,

Jan 30, 2023

  Read more at Precision Oncology News...
FDA Grants Breakthrough Device Designation to OncobiotaLUNG Assay for Lung Cancer Detection

FDA Grants Breakthrough Device Designation to OncobiotaLUNG Assay for Lung Cancer Detection

Jan 30, 2023

The FDA has granted the OncobiotaLUNG assay a breakthrough device designation for the early detection of lung cancer. The FDA has provided the OncobiotaLUNG assay a breakthrough device designation, according to the device maker, Micronoma.1 The OncobiotaLUNG assay is...
Micronoma Receives FDA Breakthrough Device Designation for OncobiotaLUNG, A Novel Liquid Biopsy Assay for Lung Carcinoma Detection

Micronoma Receives FDA Breakthrough Device Designation for OncobiotaLUNG, A Novel Liquid Biopsy Assay for Lung Carcinoma Detection

Jan 30, 2023

Micronoma, the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA). As a...
« Older Entries

Designed by Elegant Themes | Powered by WordPress